Cargando…

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy

In recent years, molecular characterization and management of patients with systemic mastocytosis (SM) have greatly benefited from the application of advanced technologies. Highly sensitive and accurate assays for KIT D816V mutation detection and quantification have allowed the switch to non-invasiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martelli, Margherita, Monaldi, Cecilia, De Santis, Sara, Bruno, Samantha, Mancini, Manuela, Cavo, Michele, Soverini, Simona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312790/ https://www.ncbi.nlm.nih.gov/pubmed/32498255 http://dx.doi.org/10.3390/ijms21113987

Ejemplares similares

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment
por: Monaldi, Cecilia, et al.
Publicado: (2021)

Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia
por: De Santis, Sara, et al.
Publicado: (2022)

The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities
por: Bruno, Samantha, et al.
Publicado: (2021)

SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023)

Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
por: Soverini, Simona, et al.
Publicado: (2021)

Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022)

Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights
por: Iezza, Miriam, et al.
Publicado: (2023)

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors
por: Mancini, Manuela, et al.
Publicado: (2022)

P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
por: Mancini, M., et al.
Publicado: (2022)

Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update
por: Bavaro, Luana, et al.
Publicado: (2019)

Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors
por: Mancini, M., et al.
Publicado: (2019)

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy
por: Soverini, Simona, et al.
Publicado: (2018)

Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021)

Recent advances in diagnosis and therapy in systemic mastocytosis
por: Lee, Hyun Jung
Publicado: (2023)

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia
por: Mancini, Manuela, et al.
Publicado: (2017)

Recent advances in the understanding and therapeutic management of mastocytosis
por: Rossignol, Julien, et al.
Publicado: (2019)

Current Concepts on Diagnosis and Treatment of Mastocytosis
por: Magliacane, D., et al.
Publicado: (2014)

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
por: Martinelli, G, et al.
Publicado: (2018)

Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications
por: Bossi, Grazia, et al.
Publicado: (2023)

Targeted Treatment Options in Mastocytosis
por: Vaes, Mélanie, et al.
Publicado: (2017)

Delayed Diagnosis of Adult Indolent Systemic Mastocytosis
por: Mikkelsen, Carsten Sauer, et al.
Publicado: (2014)

Case Report: Mastocytosis: The Long Road to Diagnosis
por: Rama, Tiago Azenha, et al.
Publicado: (2021)

Transcriptomic profiling does not refine mastocytosis diagnosis
por: Buschhorn, Lars, et al.
Publicado: (2023)

14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia
por: Mancini, Manuela, et al.
Publicado: (2015)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Mastocytosis, MCAS, and Related Disorders—Diagnosis, Classification, and Therapy
por: Niedoszytko, Marek, et al.
Publicado: (2021)

Simultaneous diagnosis of papillary thyroid cancer and systemic mastocytosis
por: Brown, Kevin F., et al.
Publicado: (2023)

Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives
por: Russo, Domenico, et al.
Publicado: (2020)

Histopathology and Molecular Genetics in Systemic Mastocytosis: Implications for Clinical Management
por: Crupi, Francesca, et al.
Publicado: (2022)

Ileal Pouch Biopsy Triggers Investigation and Diagnosis of Systemic Mastocytosis
por: Mannan, Abul Ala Syed Rifat, et al.
Publicado: (2016)

Diagnosis of indolent systemic mastocytosis in a patient with “seborrheic keratosis”
por: Moshref Razavi, Habib, et al.
Publicado: (2022)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Cutaneous mastocytosis in childhood
por: Nemat, Katja, et al.
Publicado: (2022)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis
por: Mannelli, Francesco
Publicado: (2020)

Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
por: Soverini, Simona, et al.
Publicado: (2019)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

Mastocytosis and systemic sclerosis: a clinical association
por: Bagnato, Gianluca, et al.
Publicado: (2016)

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
por: Soverini, Simona, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_61i07idoljhjp01iifjirrqgl9